To the best of our knowledge this is the first clinical trial that supports this indication for saffron.
Supporting this indication, a pair of registrational trials was conducted that enrolled the full spectrum of patients who, by guidelines, were eligible for anticoagulation.
Calculation of average strengths of the mutators obtained in acquiring n-butanol tolerance (BtlR group, 959.8-fold increase), kanamycin resistance (KanR group, 375.3-fold increase), and acetate tolerance (AceR group, 249.4-fold increase) also supported this indication.
However, recent data (Petersen et al. 2005) conflict with evidence in support of this indication (Tabet et al. 2000).
In that sense, we cannot comment directly on this use of HFOV, although some may draw support for this indication from the improvements in oxygenation as documented here.
Thrombolytic therapy does not appear to present an adequate balance between efficacy and safety; its use is therefore not supported for this indication.
This finding does not support the indication that solely early identification as well as treatment of patients with severe sepsis with standard supportive care is responsible for improved outcome after early treatment with DrotAA [ 53].
The application of liver support devices for this indication has been disappointing, although further analysis in certain subgroups of patients might be warranted [ 99, 100].
Using this model, we examined the cost-effectiveness of ITP treatment in which rituximab, for which clinical trials are underway to support approval for this indication in Japan, is added to splenectomy and the TPO-RA romiplostim, which are currently indicated for the treatment of ITP in Japan.
